Pursuit Vascular announced that it has received CE Mark approval and Medical Device Single Audit Program certificates for its ClearGuard HD caps.
“The CE Mark and MDSAP approvals are significant accomplishments for Pursuit Vascular as it allows the company to expand sales to Europe and other key international markets,” Doug Killion, president and CEO of Pursuit Vascular, said in a press release. “We look forward to working with hospitals and physicians in these countries to bring this lifesaving technology to more patients worldwide.”
ClearGuard HD has shown approximately 70% reduction in bloodstream infections in tests compared to patients who use standard caps or needless connectors. It is one of the only devices that is designed to kill infection-causing microorganisms inside a catheter between dialysis treatments.
“The extraordinary success of ClearGuard HD caps in the U.S. clearly demonstrates that we’ve been able to provide a highly effective product that is rapidly becoming the standard of care for dialysis treatment,” Killion said. “Pursuit Vascular is committed to creating technologies that aid in the prevention of catheter-related infection to enhance and extend the lives of patients around the world, and to reduce healthcare costs.”
